TP53 and gastric cancer: A study from the Asian Cancer Research Group (ACRG) clarified GC based on gene expression data into four subtypes associated with distinct clinical outcomes: MSI, MSS/EMT (microsatellite stable and epithelial-to-mesenchymal transition), MSS/TP53+ (TP53 active), and MSS/TP53− (TP53 inactive).